Aducanumab (Aduhelm), the first new drug to treat Alzheimer's disease since 
2003, has received accelerated approval from the Food and Drug Administration 
(FDA).This drug's approval has been highly contentious in the medical and 
scientific community owing to contradictory study findings and the FDA's 
advisory panel not recommending its approval.